Citius Oncology (CTOR) Corporate presentation summary

Company overview and strategy

• Focuses on developing and commercializing targeted oncology therapies, operating as a stand-alone public company since August 2024.

• Majority-owned subsidiary of Citius Pharmaceuticals, leveraging shared management for operational efficiency.

• Mission centers on delivering innovative therapies to transform patient outcomes.

• Rights to all markets except India, Japan, and certain parts of Asia.

• Estimated $400M+ addressable U.S. market for lead product.

Lead product: LYMPHIR launch and clinical profile

• First commercial product, LYMPHIR, launched in December 2025 for relapsed/refractory Stage I-III CTCL.

• Only FDA-approved IL-2 receptor-directed therapy for CTCL, with a novel mechanism targeting malignant T-cells and Tregs.

• Demonstrated 36% objective response rate, rapid median response time of 1.4 months, and durable disease control (median 6.5 months).

• Well-tolerated safety profile with most adverse events being grade 1/2 and no cumulative toxicity.

• Commercial supply distributed nationwide, accessible to providers and patients.

Market positioning and competitive differentiation

• Unique among systemic therapies, requiring no biomarker and offering a broad label.

• Competitively priced, with no new therapy approved for CTCL since 2018.

• Outperforms existing treatments in terms of response rate, safety, and quality of life impact.

• 12 years of BLA exclusivity, orphan drug designation, and complex proprietary manufacturing process create strong barriers to entry.